Drug Trial Radar · NCT03343704
This Study Looks at the Effects of Idarucizumab in Patients Who Take Dabigatran and Need Emergency Surgery or Are Bleeding
Last checked: Nov 20, 2026Latest source record: Feb 25, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
19
Actual
Start
Mar 26, 2018
Primary completion
Jul 2, 2020
Study completion Jul 2, 2020
Sponsor
- Lead sponsor
- Boehringer IngelheimBoehringer Ingelheim
- Sponsor type
- Industry
- First posted
- Nov 17, 2017
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective is to demonstrate reversal of the anticoagulant effect of dabigatran in patients treated with dabigatran etexilate who have uncontrolled or life-threatening bleeding requiring urgent intervention, and in patients treated with dabigatran etexilate who require emergency surgery or other invasive procedure. The secondary objectives are to assess the reduction or cessation of bleeding, evaluate the clinical outcomes, safety and the pharmacokinetics of dabigatran in the presence of idarucizumab.
Conditions
- Hemorrhage
Interventions
IdarucizumabDrug
Intravenous
Primary outcomes
What the sponsor says the trial is designed to measure.
- Maximum Reversal of Anticoagulant Effect of Dabigatran Based on Central Laboratory Determination of Ecarin Clotting TimeTime frame: From the end of first infusion up to 4 hours after the completion of the second infusion on Day 1 of the treatment period.
- Maximum Reversal of Anticoagulant Effect of Dabigatran Based on Central Laboratory Determination of Diluted Thrombin TimeTime frame: From the end of first infusion up to 4 hours after the completion of the second infusion on Day 1 of the treatment period.
Locations
13 sites in 1 country. Site status is shown where the registry gives one.
Beijing AnZhen Hospital
Beijing, China
Peking University First Hospital
Beijing, China
Cardiovascular Institute and Fu Wai Hospital
Beijing, China
First Affiliated Hospital of Dalian Medical University
Dalian, China
Guangdong Provincial People's Hospital
Guangzhou, China
Sun yet-sen Memorial Hospital, Sun yet-sen Univesity
Guangzhou, China
2nd Affiliated Hosp Zhejiang University College of Medical
Hangzhou, China
Zhejiang Province People's Hospital
Hangzhou, China
The Second Affiliated Hospital to Nanchang University
Nanchang, China
Jiangsu Province Hospital
Nanjing, Jiangsu Province, China
Shanghai First People's Hospital
Shanghai, China
The First Affiliated Hospital of Xinjiang Medical University
Ürümqi, China
The First Affiliated Hospital of Wenzhou Med College
Wenzhou, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.